Trial Profile
A randomized, open label, 4 period crossover study in healthy subjects to determine the effect of particle size on the pharmacokinetics of a single mg dose of GW856553.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Losmapimod (Primary)
- Indications Atherosclerosis; Chronic obstructive pulmonary disease; Depressive disorders; Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 28 Aug 2007 New trial record.